BCMA-Specific CAR-Expressing T Lymphocytes Myeloma Trials

BCMA-specific CAR-expressing T Lymphocytes is a BCMA targeted CAR T Cell therapy being developed at the Fred Hutchinson Cancer Research Center.

SparkCures ID	333
Generic Name	BCMA-Specific CAR-Expressing T Lymphocytes
Treatment Classifications	CAR T Cell
Treatment Targets	B-Cell Maturation Antigen (BCMA)

December 07, 2019

Eight patients, with a median age of 64.5 (range, 50-70 years) and a median of 10 prior regimens (range, 4-23), were screened, and seven patients have been treated.
High-risk features were present in 75% of patients
Following 3 oral doses (run in) of JSMD194, the percent of plasma cells expressing BCMA increased from 75% to 99% (7.6 to 98% pre, 75 to 100% post), soluble BCMA decreased by 2.0 fold (range 1.6 to 2.6 fold) after 3 oral doses, and BCMA antigen binding capacity increased from a median of 718 receptors to 13355 receptors per cell, or a median of 20-fold (range, 7.55-fold to 156.68-fold).
Among 6 assessable patients, the best overall response rate was 100% (5 VGPR, 1 PR), with 5/6 patients MRD negative by flow. At data cutoff of July 15, 2019, no patient has relapsed, with a median follow-up of 5 months (range 1-11 months).

BCMA-Specific CAR-Expressing T Lymphocytes